4.5 Article Retracted Publication

被撤回的出版物: Vitamin D levels do not predict cardiovascular events in statin-treated patients with stable coronary disease (Retracted article. See vol. 166, 2013)

期刊

AMERICAN HEART JOURNAL
卷 164, 期 3, 页码 387-393

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.ahj.2012.06.016

关键词

-

资金

  1. Pfizer, Inc.
  2. Pfizer
  3. GlaxoSmithKline
  4. Hoffman La Roche
  5. Gilead
  6. NIH/Abbott
  7. Spirocor Ltd
  8. NIH/Yale
  9. Kowa
  10. Amarin
  11. CV Therapeutics
  12. Sanofi-Aventis
  13. Schering-Plough
  14. AstraZeneca
  15. Abbott
  16. Merck
  17. Boston Scientific
  18. Medtronic
  19. Gilead Sciences
  20. Genzyme
  21. Eli Lilly
  22. National Heart, Lung, and Blood Institute
  23. Anthera
  24. Aegerion
  25. Biosante
  26. Bristol-Myers Squibb
  27. Cerenis
  28. Genentech
  29. Merck/Schering-Plough
  30. Roche CSL
  31. Amgen
  32. Pfizer Inc

向作者/读者索取更多资源

Background This post hoc nested case-control analysis of the TNT study was designed to investigate whether baseline vitamin D level is a significant predictor of cardiovascular risk among statin-treated patients and whether changes in vitamin D after treatment with atorvastatin are associated with improved cardiovascular outcomes. Methods A total of 10,001 patients with stable coronary heart disease were randomized to atorvastatin 80 or 10 mg for a median of 4.9 years. This analysis included 1,509 patients (497 with a subsequent cardiovascular event and 1,012 without an event) with vitamin D levels determined at baseline and 1 year. Event rates were analyzed by Cox proportional hazard model by baseline vitamin D levels, with vitamin D as a continuous variable, and with change in vitamin D level as the predictor. Results Vitamin D deficiency (<15 ng/mL) or insufficiency (15-<30 ng/mL) was present in 108 (7.2%) of 1,509 and 625 (41.4%) of 1,509 of patients, whereas 46 (3.0%) of 1,509 had elevated vitamin D. There was no relationship between baseline vitamin D levels or change in vitamin D levels and cardiovascular events or mortality. Modeling of events with vitamin D as a continuous variable similarly showed no relationship of vitamin D to events. These findings held true after adjustment for seasonal variations in vitamin D and other confounders. Conclusion In statin-treated patients with stable coronary heart disease, vitamin D levels did not predict cardiovascular risk. Changes in plasma concentrations of vitamin D after 1 year of treatment made no contribution to the efficacy of atorvastatin therapy. (Am Heart J 2012;164:387-93.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据